ArticleFrontiers in endocrinology2026
The dynamic trajectory of circulating exosome components in high-fat diet-induced metabolic-associated steatotic liver disease and its modulation by curcuminoids.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Circulating exosomes have emerged as promising non-invasive carriers of disease biomarkers, particularly in metabolic-associated steatotic liver disease (MASLD). Curcuminoids derived from Methods: A time-course mouse model of HFD-induced MASLD was established over 12 weeks. Untargeted metabolomics combined with temporal clustering analysis and nanoparticle tracking analysis was used to profile dynamic changes in circulating exosomal lipids and identify candidate biomarkers. Subsequently, the curcuminoids were administered preventively to HFD-fed mice, and targeted metabolomic analysis of the selected biomarkers was performed to assess intervention-induced alterations and their correlation with exosome particle concentration. Results: Seventy-one time-independent differential metabolites were identified between HFD and control groups. Temporal clustering analysis revealed distinct dynamic patterns of 43 metabolites between MASLD and control mice. Correlation analysis with exosome secretion dynamics identified 36 metabolites significantly associated with exosomal particle concentration, among which 26 were ultimately selected as robust lipid biomarkers. The curcuminoids significantly ameliorated MASLD-related phenotypes, including serum lipids, liver enzymes, hepatic steatosis, and brown adipose tissue injury. Quantitative analysis further showed that 22 of the 26 biomarkers were significantly downregulated by curcuminoids, with these changes correlating with exosomal particle concentration. Conclusion: This study provides a comprehensive temporal landscape of exosomal metabolite changes during MASLD progression and demonstrates that curcuminoids intervention is associated with modulation of disease progression, paralleled by downregulation of exosome-associated lipid metabolites. The identified metabolites represent potential early-stage, non-invasive biomarkers for MASLD that warrant further validation in human cohorts and offer preliminary experimental evidence for the effects of the curcuminoids in MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.